Literature DB >> 28643111

Thymic carcinoma initially presented with geographic destruction of scapula in a child.

Won-Jong Bahk1, An-Hi Lee2, Eun-Deok Chang2, Dong-Wook Min2, Yong-Koo Kang2.   

Abstract

As the conventional histopathologic examination of thymic carcinoma (TC) is nonspecific, immunohistochemical studies along with correlative radiographic investigations are needed for its correct diagnosis. TC commonly occurs in the late 5th to early 6th decades of life but is extremely rare in childhood. It may be incidentally detected from chest radiographs taken as routine or for other reasons. However, most patients present with symptoms such as chest pain, cough, shortness of breath, dysphagia and hoarseness, which are directly attributable to the mediastinal mass. Although TC frequently invades the neighboring organs, pleura and pericardium and metastasizes to the lymph nodes, liver and lung at the time of the first diagnosis, initial or late metastasis to the bone has been seldom reported in adults. Indeed, the English literature revealed no earlier report on initial bony metastasis in a child to date. We report a case of TC in a 12-year-old boy who initially presented with scapular osteolysis masquerading as a primary bone tumor to emphasize the usefulness of combined imaging for staging and histologic studies, particularly for such an unexpected case.

Entities:  

Keywords:  Child; Metastasis; Primary bone tumor; Scapula; Thymic carcinoma

Mesh:

Substances:

Year:  2017        PMID: 28643111     DOI: 10.1007/s00256-017-2696-4

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  22 in total

Review 1.  Thymic carcinoma--analysis of nineteen clinicopathological studies.

Authors:  D A Chung
Journal:  Thorac Cardiovasc Surg       Date:  2000-04       Impact factor: 1.827

Review 2.  Imaging of thymic epithelial neoplasms.

Authors:  Melissa L Rosado-de-Christenson; Diane C Strollo; Edith M Marom
Journal:  Hematol Oncol Clin North Am       Date:  2008-06       Impact factor: 3.722

3.  MR imaging of thymic epithelial tumors: correlation with World Health Organization classification.

Authors:  Atsuo Inoue; Noriyuki Tomiyama; Kiminori Fujimoto; Junko Sadohara; Itsuko Nakamichi; Yasuhiko Tomita; Katsuyuki Aozasa; Mitsuko Tsubamoto; Sachiko Murai; Javzandulam Natsag; Hiromitsu Sumikawa; Naoki Mihara; Osamu Honda; Seiki Hamada; Takeshi Johkoh; Hironobu Nakamura
Journal:  Radiat Med       Date:  2006-04

Review 4.  Two Cases of Thymic Carcinoma Initially Presenting as Bone Metastasis: A Clinical Report and the Usefulness of CD5 Immunohistochemistry for Assessing Bone Lesions.

Authors:  Shigeru Sasaki; Toshirou Fukushima; Yasuhiro Maruyama; Daisuke Gomi; Takashi Kobayashi; Nodoka Sekiguchi; Akiyuki Sakamoto; Tomonobu Koizumi; Kiyoshi Kitano
Journal:  Intern Med       Date:  2015-07-15       Impact factor: 1.271

5.  Malignant thymic epithelial tumors: CT-pathologic correlation.

Authors:  K J Jung; K S Lee; J Han; J Kim; T S Kim; E A Kim
Journal:  AJR Am J Roentgenol       Date:  2001-02       Impact factor: 3.959

Review 6.  Thymic carcinoid tumors with bone metastases. A report of two cases.

Authors:  B A Georgy; G Casola; J R Hesselink
Journal:  Clin Imaging       Date:  1995 Jan-Mar       Impact factor: 1.605

Review 7.  Metastatic thymic carcinoma in a digit: a case report.

Authors:  F J Shannon; C R Antonescu; E A Athanasian
Journal:  J Hand Surg Am       Date:  2000-11       Impact factor: 2.230

8.  KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas.

Authors:  Chin-Chen Pan; Paul Chih-Hsueh Chen; Hung Chiang
Journal:  J Pathol       Date:  2004-03       Impact factor: 7.996

Review 9.  Thymic carcinoma: current concepts and histologic features.

Authors:  Cesar A Moran; Saul Suster
Journal:  Hematol Oncol Clin North Am       Date:  2008-06       Impact factor: 3.722

10.  Thymic carcinoma. A clinicopathologic study of 60 cases.

Authors:  S Suster; J Rosai
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.